Serum spla2-iia as diagnosis marker for prostate and lung cancer

A kit for assessing lung cancer in patients with solitary pulmonary nodules, the kit comprising:

• reagents for detection and/or quantification of serum secretory phospholipase A2-IIA in plasma, wherein the reagents for detection and/or quantification of serum secretory phospholipase A2-IIA in plasma comprise:
• a capture antibody having specific binding affinity to the serum secretory phospholipase A2-IIA in the plasma,
• an enzyme conjugated to a detection antibody having specific binding affinity to the serum secretory phospholipase A2-IIA in the plasma, and
• a substrate of the enzyme conjugated to the detection antibody having specific binding affinity to the serum secretory phospholipase A2-IIA in the plasma, wherein action of the enzyme conjugated to the detection antibody having specific binding affinity to the serum secretory phospholipase A2-IIA in the plasma upon the substrate produces at least one detectable product;
• reagents for detection and/or quantification of carcinoembryonic antigen in plasma, wherein the reagents for detection and/or quantification of carcinoembryonic antigen in plasma comprise:
• a capture antibody having specific binding affinity to the carcinoembryonic antigen in the plasma,
• an enzyme conjugated to a detection antibody having specific binding affinity to the carcinoembryonic antigen in the plasma, and
• a substrate of the enzyme conjugated to the detection antibody having specific binding affinity to the carcinoembryonic antigen in the plasma, wherein action of the enzyme conjugated to the detection antibody having specific binding affinity to the carcinoembryonic antigen in the plasma upon the substrate produces at least one detectable product;
• and
• reagents for detection and/or quantification of cytokeratin-19 fragment in plasma, wherein the reagents for detection and/or quantification of cytokeratin-19 fragment in plasma comprise:
• a capture antibody having specific binding affinity to the cytokeratin-19 fragment in the plasma,
• an enzyme conjugated to a detection antibody having specific binding affinity to the cytokeratin-19 fragment in the plasma, and
• a substrate of the enzyme conjugated to the detection antibody having specific binding affinity to the cytokeratin-19 fragment in the plasma, wherein action of the enzyme conjugated to the detection antibody having specific binding affinity to the cytokeratin-19 fragment in the plasma upon the substrate produces at least one detectable product.

An in vitro method for assessing lung cancer in a patient, the method comprising:

• (a) contacting a portion of a sample from the patient with:
• a specific binding agent for serum secretory phospholipase A2-IIA,
• a specific binding agent for carcinoembryonic antigen, and
• a specific binding agent for cytokeratin-19 fragment;
• (b) calculating levels of serum secretory phospholipase A2-IIA, carcinoembryonic antigen, and cytokeratin-19 fragment based on the contacting in step (a);
• and
• (c) assessing as indicating lung cancer in the patient if the calculated levels of serum secretory phospholipase A2-IIA, carcinoembryonic antigen, and/or cytokeratin-19 fragment are elevated relative to cutoff values of serum secretory phospholipase A2-IIA, carcinoembryonic antigen, and cytokeratin-19.